ChemicalBook > Product Catalog >API >Antibiotics >Tetracycline drugs >Tigecycline


Tigecycline Suppliers list
Company Name: Nanjing Gold Pharmaceutical Technology Co. Ltd.
Tel: 025-84209270 15906146951
Products Intro: Product Name:Tigecycline
Purity:99% Package:1000KG;;100KG;10KG;5KG;1KG
Company Name: Lianyungang happen teng technology co., LTD
Tel: 15950718863
Products Intro: Product Name:Tigecycline
Purity:98.00% Package:1kg,2kg,4kg,6kg,10kg
Company Name: Capot Chemical Co.,Ltd.
Tel: +86-571-85586718
Products Intro: Product Name:Tigecycline
Purity:98%(Min,HPLC) Package:100g;1kg;5kg,10kg,25kg,50kg
Company Name: Henan Tianfu Chemical Co.,Ltd.
Tel: 0371-55170693
Products Intro: Product Name:220620-09-7
Purity:0.99 Package:25KG,5KG;1KG;500G
Company Name: PI & PI BIOTECH INC.
Tel: 18371201331
Products Intro: Product Name:Tigecycline
Purity:90%+ Package:10mg, 25mg, 50mg, 100mg, Other scale please email Remarks:(4S,4aS,5aR,12aS)-9-[2-(tert-Butylamino)acetamido]-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide

Lastest Price from Tigecycline manufacturers

  • Tigecycline
  • US $0.00 / KG
  • 2020-10-30
  • CAS:220620-09-7
  • Min. Order: 100g
  • Purity: 98%+
  • Supply Ability: 100kg
  • Tigecycline
  • US $0.00-0.00 / KG
  • 2020-07-22
  • CAS:220620-09-7
  • Min. Order: 1g
  • Purity: 99.0%
  • Supply Ability: 5kg/month
  • Tigecycline
  • US $0.00-0.00 / 公斤
  • 2020-05-25
  • CAS:220620-09-7
  • Min. Order: 1公斤
  • Purity: 99.0%+
  • Supply Ability: 300 MT
Tigecycline Basic information
Indications and Usage Mechanisms of Action Adverse reaction
Product Name:Tigecycline
Synonyms:(4s,4as,5ar,12as)-4,7-bis(dimethylamino)-9-[(tert-butylamino)acetamido]-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracen-2-carboxamide;2-NAPHTHACENECARBOXAMIDE, 4,7-BIS(DIMETHYLAMINO)-9-[[[(1,1-DIMETHYLETHYL)AMINO]ACETYL]AMINO]-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-, (4S,4AS,5AR,12AS)-;ecycL;Tig;tigecycline;TIGECYCLINE GLYCYLCYCLINE;(4S,4As,5aR,12as)-4,7-Bis(dimethylamino)-9-{(tert-butylamino)acetamido}-3,10,12,12a-octahydrotetracen-2-carboxamide;2-NAPHTHACENECARBOXAMIDE
Product Categories:pharmaceutical intermediate;Amines;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals;API;Antibacterial
Mol File:220620-09-7.mol
Tigecycline Structure
Tigecycline Chemical Properties
Melting point 164-166°C
Boiling point 890.9±65.0 °C(Predicted)
density 1.45±0.1 g/cm3(Predicted)
storage temp. Amber Vial, -20°C Freezer
form Orange powder
Merck 14,9432
CAS DataBase Reference220620-09-7(CAS DataBase Reference)
Safety Information
Safety Statements 24/25
RTECS QI7619500
HazardClass 9
PackingGroup III
HS Code 29419090
MSDS Information
Tigecycline Usage And Synthesis
Indications and UsageTigecycline is also called 9-tert-glycylaminomycetine or diclofenac, and it is a new type of venous injection antibiotic with broad-spectrum activities. It is a type of 9-tert-glycylaminomycetine derivative and is the first glycylcine antibiotic.
Tigecycline can serve as a second option after failed first-line treatment for multi-drug resistant bacteria, and it is also a new treatment option for patients who are allergic to penicillin or intolerable to other drugs. It can treat patients 18 years old or above with complex skin and skin structure infections or complex abdominal infections such as complex appendicitis, burn infections, abdominal abscesses, deep soft tissue infections, and ulcer infections.
Mechanisms of ActionTigecycline’s mechanisms of action are similar to those of tetracycline antibiotics, which are binding with bacterial 30S ribosomes to prevent transfer RNA from entering, making it impossible for amino acids to form peptide chains, thus preventing bacterial protein synthesis and limiting bacterial growth. However, tigecycline’s ability to bind with ribosomes is 5 times that of other tetracycline antibiotics, which means that tetracycline’s anti-drug resistance ability is stronger. Tigecycline’s structure is similar to that of minocycline, but tigecycline’s antibacterial activity is much stronger, and bacteria are less likely to develop resistance to it compared to other tetracycline drugs, and it can also act on the methicillin-resistant Staphylococcus aureus. Tigecycline’s antifungal spectrum includes gram-positive bacteria, gram-negative bacteria and anaerobic bacteria. In vitro experiments and clinical trials showed that tigecycline is sensitive to some aerobic gram-negative bacteria (such as Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae and Klebsiella pneumoniae, Acinetobacter baumannii, Aeromonas hydrophila, Citrobacter Enterobacteriaceae, hemorrhagic Pasteurella, Serratia marcescens, and Stenotrophomonas maltophilia). Pseudomonas auruginosa is resistant to tigecycline.
Adverse reactionThe most common adverse effects are nausea and vomiting, which usually happens in the first 1-2 days of treatment and are mild to moderate in intensity. In a positive drug control clinical trial, 35% percent of complex skin and skin structure infection patients using tigecycline experienced nausea, and 20% experienced vomiting; vancomycin/aztreonam use caused 8.9% nausea and 4.2% vomiting. 25.3% of complex abdominal infection patients using tigecycline experienced nausea, and 19.5% experienced vomiting; vancomycin/aztreonam caused 20.5% nausea and 15.3% vomiting.
DescriptionThe emergence of drug-resistant bacteria has diminished the clinical utility of the tetracyclines. Research to circumvent the efflux and ribosomal protection mechanisms of bacteria has led to the development of the glycylcyclines. Tigecycline is the first glycylcycline antibiotic to launch for the parenteral treatment of baterial infection, including complicated intra-abdominal and skin infections. Its mechanism of action involves inhibiting protein translation in bacteria by binding to the 30S ribosomal subunit and blocking entry of amino-acyl tRNA molecules into the A site of the ribosome to effectively prevent incorporation of amino acid residues into elongating peptide chains. Presumably, ribosomal protection proteins are ineffective against tigecycline due to its higher affinity for ribosomal binding compared to tetracyclines (approximately 16-fold). In addition, tigecycline may be resistant to efflux mechanisms by either their inability to translocate it across the cytoplasmic membrane due to steric complications or simply by their failure to recognize the molecule. The most common adverse events were nausea and vomiting. Tigecycline was also evaluated in patients with complicated skin and soft tissue infections in a separate phase II trial. Patients were randomized to receive either tigecycline 50 mg i.v. followed by 25mg i.v. every 12 h or tigecycline 100 mg i.v. followed by 50 mg i.v. every 12 h. Slightly higher cure rates were observed in the 50 mg group (74%) compared to the 25 mg group (67%). Pathogens were also eradicated more frequently in the 50-mg group (69%) compared to the 25 mg group (56%). Both doses were well tolerated with nausea and vomiting again being the most common adverse effects. From the combined clinical data, the recommended dosage regimen for tigecycline is an initial dose of 100 mg, followed by 50mg every 12 h by i.v. infusion over 30–60 min. Being structurally similar to the tetracycline class of antibiotics, similar adverse effects and warnings apply. As with tetracyclines, tigecycline should not be administered to pregnant women due to the potential for fetal harm. Furthermore, the use of tigecycline should be avoided during tooth development (last half of pregnancy, infancy, and childhood to the age of 8 years) because permanent discoloration of the teeth may occur.
Chemical PropertiesOrange Solid
OriginatorWyeth (US)
UsesTigecycline is a semi-synthetic tetracycline prepared by the introduction of a tert-butylaminoacetamido group into a previously unexplored and un-substituted region of existing tetracyclines. Like other tetracyclines, tigecycline acts by reversibly binding to the 30S ribosomal subunit and inhibits protein translation by blocking entry of aminoacyl-tRNA into the ribosome A site. The enhanced activity can be attributed to stronger binding affinity, thus minimising the impact of existing mechanisms of resistance. Tigecycline is regarded as the first of a new class of glycylcyline antibiotics. Critical comparison to the tetracycline class appears to be lacking in the literature.
UsesA broad spectrum glycylcycline antibiotic
UsesA glycylcycline antibiotic, used to treat infection by drug resistant bacteria such as Staphylococcus aureus (Staph aureus) and Acinetobacter baumannii.
DefinitionChEBI: Tetracycline in which the hydroxy group at position 5 and the methyl group at position 6 are replaced by hydrogen, and with a dimethylamino substituent and an (N-tert-butylglycyl)amino substituent at positions 7 and 9, respe tively. A glycylcycline antibiotic, it has activity against a broad range of Gram-positive and Gram-negative bacteria, including tetracycline-resistant organisms. It is used for the intravenous treatment of complicated skin and skin structure infections ca sed by susceptible organisms.
Brand nameTygacil
Antimicrobial activityIt is as potent as, or more potent than, earlier tetracyclines and activity is retained against strains expressing acquired tetracycline resistance determinants. It displays better activity than tetracycline, doxycycline or minocycline against Streptococcus spp. and against Enterococcus faecalis and E. faecium. Among Gram-negative organisms it displays improved activity against Citrobacter freundii, Escherichia coli, Enterobacter cloacae, Klebsiella pneumoniae, Salmonella spp., Serratia marcescens and Shigella spp. The spectrum includes rapidly growing mycobacteria. Ps. aeruginosa, Pr. mirabilis, other Proteus spp. and some strains of Corynebacterium jeikeium are resistant. Activity against strains expressing acquired resistance to earlier tetracyclines is attributed to failure of the MFS efflux pumps to recognize tigecycline, and to a novel mechanism of ribosome binding that permits tigecycline to overcome ribosomal protection mechanisms.
Comparative susceptibility data for some atypical pathogens are not available. However, in common with earlier tetracyclines, it is active against Chlamydophila and Mycoplasma spp. and rapidly growing Mycobacteria spp. It is less active than minocycline or tetracycline against U. urealyticum.
General DescriptionTigecycline (Tygacil) is a first-in-class (a glycylcycline) intravenousantibiotic that was designed to circumvent manyimportant bacterial resistance mechanisms. It is not affectedby resistance mechanisms such as ribosomal protection, effluxpumps, target site modifications, β-lactamases, or DNAgyrase mutations. Tigecycline binds to the 30S ribosomalsubunit and blocks peptide synthesis. The glycylcyclinesbind to the ribosome with five times the affinity of commontetracyclines. Tigecycline also possesses a novel mechanismof action, interfering with the mechanism of ribosomal protectionproteins. Tigecycline, unlike common tetracyclines,is not expelled from the bacterial cell by efflux pumpingprocesses.
Tigecycline is recommended for the treatment of complicatedskin and skin structure infections caused by E. coli,E. faecalis (vancomycin-susceptible isolates), S. aureus(methicillin-susceptible and methicillin-resistant isolates),S. pyogenes, and B. fragilis among others. Tigecycline is alsoindicated for complicated intra-abdominal infections causedby strains of Clostridium, Enterobacter, Klebsiella, andBacteroides. To reduce the development of resistance to tigecycline,it is recommended that this antibiotic be used onlyfor those infections caused by proven susceptible bacteria.Glycylcyclines are structurally similar to tetracyclines,and appear to have similar adverse effects. These mayinclude photosensitivity, pancreatitis, and pseudotumorcerebri. Nausea and vomiting have been reported.
Pharmaceutical Applications9-T-butylglycylamido-minocycline. A compound of the glycylcycline class available as a powder for intravenous infusion.
PharmacokineticsCmax 100 mg intravenous infusion (1 h): 0.85–1 mg/L
Plasma half-life: 37–67 h
Volume of distribution: 7–10 L/kg
Plasma protein binding: 68%
Distribution and excretion
It is widely distributed and is concentrated in the gallbladder, colon and lung. The volume of distribution is dose related and variable, but is generally greater than that of older tetracyclines. CSF penetration is poor. Tigecycline is excreted in the feces and urine predominantly as the unchanged molecule. The elimination half-life is long (37–67 h). Tigecycline clearance is decreased by 20% in patients with renal failure. No dosage adjustments are apparently necessary for tigecycline in patients with renal impairment.
Clinical UseComplicated skin and skin structure infections
Complicated intra-abdominal infections
Community-acquired bacterial pneumonia
Recommended principally for the treatment of infections with multiresistant organisms.
Side effectsSide effects typical of the group, including nausea, vomiting, diarrhea and headache, occur. Occasional cases of pancreatitis, hypoproteinemia, antibiotic-associated colitis and thrombocytopenia have also been reported.
Tigecycline Preparation Products And Raw materials
Tag:Tigecycline(220620-09-7) Related Product Information
Voriconazole 7-AMINO-3,4-DIHYDRONAPHTHALEN-1(2H)-ONE 5,6,7,8-TETRAHYDRONAPHTHALENE-2-YL-ACETAMIDE 5,6,7,8-Tetrahydro-1-naphthylamine 2-NAPHTHALENAMINE, 5,6,7,8-TETRAHYDRO- 7-Monodemethyl Minocycline 2'-HYDROXY-P-ACETOTOLUIDIDE, 98 Tigecycline N,N-Dimethylacetamide 4'-CHLOROACETANILIDE Minocycline 3-Dimethylaminopropylamine Acetaminophen Minocycline hydrochloride DIACETAMIDE tert-Butanol Thioacetamide Cyclosporin A